RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsJohn M. Yanni, John E. Chatterton, Daniel A. Gamache, Steven T. Miller
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
Claims8
A method of attenuating expression of a PDE4 mRNA in a subject, the method comprising:
- (a) administering to an eye of the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising:
- (i) any one of SEQ ID NO 146, SEQ ID NO:149-158, SEQ ID NO:161, SEQ ID NO:167, SEQ ID NO:169-171, or SEQ ID NO:173-199,
- (ii) wherein the expression of the PDE4 mRNA is attenuated thereby.
A composition comprising an interfering RNA with a sense strand having a length of 19 to 49 nucleotides containing at least one non-naturally occurring nucleotide and comprising the base sequence of any one of SEQ ID NO:5, SEQ ID NO:11-146, SEQ ID NO:149-158, SEQ ID NO:
- 161, SEQ ID NO:167, SEQ ID NO:169-171, or SEQ ID NO:173-199, or a complement thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.